Special Issue: CRISPR Trials

Ever since the development of CRISPR-Cas9 genome editing a decade ago, hopes have risen that this technology could deliver a new era of precision medicine. To date, some 200 patients have been or are currently in clinical trials for blood diseases, liver diseases, and various forms of cancer. That number is likely to grow substantially over the next few years as the first CRISPR-based therapies head to regulatory approval.

Despite this progress, there are huge challenges to overcome if the promise of CRISPR in the clinic is to be realized. They span improvements in foundational gene editing and delivery platforms to improvements in the funding, regulatory, and networking framework to expand CRISPR therapies to hundreds or thousands of rare diseases.

For our next special issue, The CRISPR Journal invites the submission of manuscripts (original research, review articles, perspectives) on all aspects of CRISPR Trials. Examples include:

• Preclinical gene editing
• Clinical trials
• Economic analysis
• Regulatory affairs
• Academic-industry patnerships
• Viral and nonviral gene delivery
• Rare diseases
• Advances in base and prime editing
• Novel gene editing tools and technologies
• Companion diagnostics

This exciting special issue will be published in early 2024. Manuscripts will receive prompt peer review and accepted articles will be published online (epub) ahead of print. Please refer to our Instructions for Authors before submitting your manuscript.

Click here to submit your paper for peer review online
Upload your manuscript under the category: Special Issue: CRISPR Trials

Benefits of publishing in The CRISPR Journal include:

• Impact Factor: 3.7
• Expert peer review and editorial oversight of your manuscript from leading specialists in your field
• Zero-embargo green open access
• Free 30-day access to share your published research with your networks and colleagues
• Global visibility in more than 170 countries worldwide  
• Gold open access options available